February 12, 2018 / 10:39 PM / in a year

Teva to pay $157 million to resolve Lidoderm pay-for-delay cases

Teva Pharmaceuticals Ltd said on Monday it would pay $157 million to resolve lawsuits alleging a drugmaker whose business it later acquired was paid by Endo International Plc to delay launching a generic version of Endo’s Lidoderm painkiller patch.

Teva disclosed in a filing with the U.S. Securities and Exchange Commission that it would pay the sum to settle claims stemming from litigation against Watson Pharmaceuticals Inc, whose generics business Teva acquired in 2015.

To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/2o1QSgg

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below